Drug intelligence / Profile preview

ketamine + amitriptyline

Development stage
Unknown
Lead developer
Aalborg University
Modality
Small Molecules
Administration
Topical
01

Overview

This is an experimental topical formulation combining ketamine and amitriptyline being investigated by Aalborg University for the treatment of itch. The formulation, typically prepared as a cream containing 0.5% ketamine and 1% amitriptyline, was evaluated in a completed mechanistic research trial (NCT06245564). Ketamine acts as an N-methyl-D-aspartate (NMDA) receptor antagonist, while amitriptyline functions as a voltage-gated sodium channel antagonist when applied topically. The combination is designed to target both histaminergic and non-histaminergic itch pathways. The study was conducted in healthy volunteers using experimentally induced itch (via histamine and cowhage) to understand the underlying mechanisms of pruritus rather than as a commercial therapeutic development program.

Other names
ketamine 0.5% + amitriptyline 1% creamtopical ketamine and amitriptyline
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on ketamine + amitriptyline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine + amitriptyline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call